Introduction to ProMMise-D: Summer webinar
About
The recent NICE approval of belantamab mafodotin in combination with bortezomib and dexamethasone (Bela-Vd) enables access for patients across the NHS to an effective new treatment option for myeloma at first relapse. Currently, patients receiving belamaf require regular ocular examinations and many centres are now considering how best to implement this requirement in their regions.ProMMise-D is a UK Myeloma Research Alliance trial, in which patients receive treatment with BelaVd. The study is designed to explore an alternative method for monitoring ocular toxicity, which could reduce healthcare costs, alleviate patient burden, and increase access to belamaf across centres. ProMMise-D will assess whether a haematology clinician-led assessment (Vision Related Anamnestic Tool, or VRAT) can be used to safely guide belamaf dosing in patients with relapsed/refractory multiple myeloma.
Location
Online event access details will be provided by the event organiser
Contact Form
Introduction to ProMMise-D: Summer webinar
Resend recently purchased tickets to our events to your email.
Enter email to start search
You can review the event organiser's terms and conditions here.